© 2005 European Society of Cardiology
Is the pregnancy hormone relaxin an important player in human heart failure?
a Division of Cardiology, Department of Medicine, Helsinki University Central Hospital Helsinki, Finland
b Department of Obstetrics and Gynaecology, Helsinki University Central Hospital Helsinki, Finland
* Corresponding author. Tel.: +358 9 47172441; fax: +358 9 47174574. E-mail address: markku.kupari{at}hus.fi
 |
Abstract |
|---|
Background: The pregnancy hormone relaxin has been raised as a new compensatory mediator of cardiac origin in heart failure (HF). We set out to assess the role of relaxin in pressure overload-induced human HF.
Methods: We studied 129 adult patients undergoing cardiac catheterization for isolated aortic valve stenosis (AS). Blood was sampled from the aortic root and, in a subset of 49 patients, from the coronary sinus for the determination of plasma relaxin by enzyme immunoassay. HF was diagnosed when the patient had dyspnea or fatigue on ordinary effort in association with pulmonary wedge pressure >14 mm Hg at catheterization.
Results: Forty-one patients had HF, which was systolic (ejection fraction <50%) in 16 patients and diastolic in 25 patients. The median plasma relaxin was 32 pg/ml (<12–297 pg/ml) in 88 AS patients without HF, 28 pg/ml (<12–825 pg/ml) in the 41 AS patients with HF, and 42 pg/ml (range, <12–100 pg/ml) in 11 control patients free of heart disease (p=0.82). Plasma relaxin did not correlate with any measurement of cardiac structure or function. The concentration gradients of relaxin from the aortic root to the coronary sinus indicated relaxin extraction by the heart in the control patients (median change, –5 pg/ml, p=0.038) vs. relaxin production in patients with systolic HF (median change, +6 pg/ml, p=0.028) (p=0.002 between groups).
Conclusions: Although the heart may release relaxin into the circulation in certain forms of HF, this does not translate into elevated systemic concentrations. Relaxin is not a major player in human HF.
Key Words: Heart failure • Aortic stenosis • Relaxin
Received June 22, 2004; Revised July 10, 2004; Accepted July 21, 2004
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. E. Shaw, P. Wood, J. Kulpa, F. H. Yang, A. J. Summerlee, and W. G. Pyle Relaxin alters cardiac myofilament function through a PKC-dependent pathway Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H29 - H36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xu, E. D. Lekgabe, X.-M. Gao, Z. Ming, G. W. Tregear, A. M. Dart, R. A. D. Bathgate, C. S. Samuel, and X.-J. Du Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis Endocrinology, February 1, 2008; 149(2): 476 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-l. Moore, S.-l. Tan, C.-y. Lo, L. Fang, Y.-D. Su, X.-M. Gao, E. A. Woodcock, R. J. Summers, G. W. Tregear, R. A. D. Bathgate, et al. Relaxin Antagonizes Hypertrophy and Apoptosis in Neonatal Rat Cardiomyocytes Endocrinology, April 1, 2007; 148(4): 1582 - 1589. [Abstract] [Full Text] [PDF]
|
|